NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

"I'm not sure if I've mentioned this to you or not, or if you already came across this... but in this video where LL is answering questions with Dr. Cobb, she states that it is the IDH1 mutation negative wild-type tumor that does well on DCVax-L."

Yes, that is the part of the video that I point to in my three recent posts. Starting at 48:10. But stated it in that fashion is not very useful for about 99% of the audience, and even confused LL, as I pointed out.

So I attempted to translate that, and was asking for verification that I translated it correctly. I would appreciate it if you would double check this, but:

1) Wild Type = prevalent genetic type
2) Not 100% certain whether methylated is more prevelant than unmethylated, but this study below observed 2/3 unmethylated, 1/3 methylated, so I am going to assume that unmethylated is generally considered wild type.
https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-10-36

On the other hand elsewhere in the report they say that methylation is reported in 30-60% of glioblastoma patients. Best guess from that is 45% which puts it awfully close to 50% which makes the term "wild-type" pretty useless and therefore inappropriate because wild vs not is purely a statement about prevalence. Still, even in this statement they are giving a slight statistical edge to unmethylated, so I will continue to assume that the wild type is unmethylated even though I do not understand why they just wouldn't spell that out.

So LL then stated that the mesenchymals are primarily unmethylated.

But please do check my reasoning and facts here.